Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 20.56% is in line with its 5-year average of 19.88%, around the middle of its 5-year range (10.98%–26.49%).
4.83% below its 12-month average of 21.60%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 20.98%.
GROSS MARGIN
20.56%
GROSS MARGIN AVG TTM
21.60%
GROSS MARGIN AVG 3Y
21.64%
GROSS MARGIN AVG 5Y
19.88%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-4.83%
CURRENT VS 3Y AVG
-4.97%
CURRENT VS 5Y AVG
+3.41%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-50.31%
vs the sector median at left
Strata Critical Medical, Inc.
Market Cap
$409.69M
Gross Margin
20.56%
TTM Avg
21.60%
3Y Avg
21.64%
5Y Avg
19.88%
Market Cap
$409.29M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$412.91M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$405.49M
Gross Margin
68.83%
TTM Avg
69.91%
3Y Avg
69.67%
5Y Avg
69.68%
Market Cap
$404.94M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
12.37%
Market Cap
$402.01M
Gross Margin
0.00%
TTM Avg
-125.52%
3Y Avg
-62.76%
5Y Avg
-41.84%
Market Cap
$417.78M
Gross Margin
61.77%
TTM Avg
80.89%
3Y Avg
90.44%
5Y Avg
-1369.52%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Strata Critical Medical, Inc. (SRTA) | $409.69M | 20.56% | 21.60% | 21.64% | 19.88% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $409.29M | 0.00% | 0.00% | 0.00% | 0.00% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $412.91M | 0.00% | 0.00% | 0.00% | 0.00% |
| Myriad Genetics, Inc. (MYGN)vs › | $405.49M | 68.83% | 69.91% | 69.67% | 69.68% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $404.94M | 0.00% | 0.00% | 0.00% | 12.37% |
| Rezolute, Inc. (RZLT)vs › | $409.72M | 0.00% | 0.00% | 0.00% | 0.00% |
| Neurogene Inc. (NGNE)vs › | $402.01M | 0.00% | -125.52% | -62.76% | -41.84% |
| Prothena Corporation plc (PRTA)vs › | $417.78M | 61.77% | 80.89% | 90.44% | -1369.52% |
| Carlsmed, Inc. (CARL)vs › | $401.25M | 76.63% | 74.56% | 73.66% | 73.66% |
| Senseonics Holdings, Inc. (SENS)vs › | $419.61M | 44.71% | 23.54% | 19.38% | -46.55% |
Gross Margin
20.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 20.98% |
| 2026-03-31 | 20.95% |
| 2025-12-31 | 17.47% |
| 2025-09-30 | 23.56% |
| 2025-06-30 | 25.05% |
| 2025-03-31 | 22.06% |
| 2024-12-31 | 23.16% |
| 2024-09-30 | 26.49% |
| 2024-06-30 | 24.07% |
| 2024-03-31 | 19.68% |
| 2023-12-31 | 18.98% |
| 2023-09-30 | 21.81% |
| 2023-06-30 | 17.00% |
| 2023-03-31 | 15.82% |
| 2022-12-31 | 13.05% |
| 2022-09-30 | 20.27% |
| 2022-06-30 | 14.34% |
| 2022-03-31 | 10.98% |
| 2021-12-31 | 22.15% |
| 2021-09-30 | 16.17% |
| 2021-06-30 | 23.48% |
| 2021-03-31 | 15.92% |
| 2020-12-31 | 20.27% |
| 2020-09-30 | 19.28% |
| 2020-06-30 | 18.44% |
| 2020-03-31 | 9.65% |
| 2019-12-31 | -10.22% |
| 2019-09-30 | 0.00% |
